IGI Logo

Cipla is currently trading at Rs. 1455.95, up by 7.70 points or 0.53% from its previous closing of Rs. 1448.25 on the BSE.

The scrip opened at Rs. 1461.00 and has touched a high and low of Rs. 1483.40 and Rs. 1449.30 respectively. So far 44841 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1702.00 on 09-Oct-2024 and a 52 week low of Rs. 1192.85 on 18-Dec-2023.

Last one week high and low of the scrip stood at Rs. 1483.40 and Rs. 1424.00 respectively. The current market cap of the company is Rs. 117124.23 crore.

The promoters holding in the company stood at 30.92%, while Institutions and Non-Institutions held 52.88% and 16.19% respectively.

Cipla has obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza (insulin human) Inhalation Powder in India. Afrezza, a product created and manufactured by MannKind Corporation (MannKind) USA, is used to improve glycemic control in adult patients with diabetes mellitus. By bringing a game-changing, patient-centered solution to diabetes management in India, Cipla will make this drug accessible to all and empower millions to take control of their health with greater ease.

Afrezza is a rapid-acting insulin delivered through an inhaler as compared to current insulins which are given as injections. Taken at the beginning of a meal, Afrezza dissolves rapidly upon oral inhalation into the lungs and delivers insulin quickly to the bloodstream. Afrezza starts working in as early as 12 minutes and helps in reducing the rapid increase seen in sugar levels with meals. The effect of Afrezza lasts for about 2-3 hours and it closely resembles the body’s own response to insulin. This is the first and only noninjectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.